RxDoctor Payments Data

Kai Quin, MD

Rheumatology · Marion, OHNPI 1639435761

Payments from drug & device makers

$3,023in general payments, 2019–2025

Across 181 payments — averaging $16.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$848
  • AbbVie$379
  • Genentech USA, Inc.$323
  • Pfizer$278
  • Novartis$266
  • UCB, Inc.$222
  • plus $706 from 9 others

What the payments were for

  • Food & beverage$2,88896%
  • Education$1364%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,023 in reported general payments places this provider in the 55th percentile of 255 rheumatology providers in Ohio.

See all rheumatology providers in Ohio

Medicare billing

Part B allowed, 2024
$177,986
Medicare patients
485
Services billed
3,417

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab74$735,729
Enbrel SureclickEtanercept28$240,981
RinvoqUpadacitinib31$194,613
Xeljanz XrTofacitinib Citrate20$145,669
Actemra ActpenTocilizumab28$144,884
Orencia ClickjectAbatacept24$136,499
Cimzia (2 Pack)Certolizumab Pegol22$135,774
Taltz AutoinjectorIxekizumab18$121,509
Enbrel MiniEtanercept12$88,220
Hydroxychloroquine Sulfate532$15,561
Leflunomide200$11,474
MethotrexateMethotrexate Sodium604$9,789
Colchicine98$7,742
Prednisone886$5,131
Celecoxib118$4,695

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$379$194,61331 claims
UCB, Inc.Cimzia (2 Pack)$222$135,77422 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 255 rheumatology providers in Ohio.

Other rheumatology in Marion

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →